vs
Side-by-side financial comparison of BUILD-A-BEAR WORKSHOP INC (BBW) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.
CATALYST PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($152.6M vs $122.7M, roughly 1.2× BUILD-A-BEAR WORKSHOP INC). CATALYST PHARMACEUTICALS, INC. runs the higher net margin — 34.5% vs 6.6%, a 27.9% gap on every dollar of revenue. On growth, CATALYST PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (7.6% vs 2.7%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $1.7M).
Build-A-Bear Workshop, Inc. is an American retailer headquartered in St. Louis, Missouri that sells teddy bears, stuffed animals, and characters. During store visits, customers go through an interactive process where the stuffed animal of their choice is assembled and tailored to their own preferences including varying scents, sounds, looks, and outfits. Build-A-Bear Workshop is the largest chain that operates in this style. The company's slogan was "Where Best Friends Are Made" from 1997–201...
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...
BBW vs CPRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $122.7M | $152.6M |
| Net Profit | $8.1M | $52.7M |
| Gross Margin | 53.7% | 82.9% |
| Operating Margin | 8.7% | 40.5% |
| Net Margin | 6.6% | 34.5% |
| Revenue YoY | 2.7% | 7.6% |
| Net Profit YoY | -17.7% | -5.8% |
| EPS (diluted) | $0.62 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $122.7M | $152.6M | ||
| Q3 25 | $124.2M | $148.4M | ||
| Q2 25 | $128.4M | $146.6M | ||
| Q1 25 | $150.4M | $141.4M | ||
| Q4 24 | — | $141.8M | ||
| Q3 24 | — | $128.7M | ||
| Q2 24 | — | $122.7M | ||
| Q1 24 | — | $98.5M |
| Q4 25 | $8.1M | $52.7M | ||
| Q3 25 | $12.4M | $52.8M | ||
| Q2 25 | $15.3M | $52.1M | ||
| Q1 25 | $21.7M | $56.7M | ||
| Q4 24 | — | $55.9M | ||
| Q3 24 | — | $43.9M | ||
| Q2 24 | — | $40.8M | ||
| Q1 24 | — | $23.3M |
| Q4 25 | 53.7% | 82.9% | ||
| Q3 25 | 57.6% | 84.7% | ||
| Q2 25 | 56.8% | 85.9% | ||
| Q1 25 | 56.6% | 87.3% | ||
| Q4 24 | — | 84.7% | ||
| Q3 24 | — | 85.0% | ||
| Q2 24 | — | 87.4% | ||
| Q1 24 | — | 87.3% |
| Q4 25 | 8.7% | 40.5% | ||
| Q3 25 | 12.3% | 44.7% | ||
| Q2 25 | 15.3% | 45.2% | ||
| Q1 25 | 18.3% | 44.8% | ||
| Q4 24 | — | 44.3% | ||
| Q3 24 | — | 39.6% | ||
| Q2 24 | — | 44.2% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | 6.6% | 34.5% | ||
| Q3 25 | 10.0% | 35.6% | ||
| Q2 25 | 11.9% | 35.6% | ||
| Q1 25 | 14.4% | 40.1% | ||
| Q4 24 | — | 39.4% | ||
| Q3 24 | — | 34.1% | ||
| Q2 24 | — | 33.2% | ||
| Q1 24 | — | 23.6% |
| Q4 25 | $0.62 | $0.40 | ||
| Q3 25 | $0.94 | $0.42 | ||
| Q2 25 | $1.17 | $0.41 | ||
| Q1 25 | $1.61 | $0.45 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | — | $0.35 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | — | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.7M | $709.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $150.6M | $954.3M |
| Total Assets | $326.5M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.7M | $709.2M | ||
| Q3 25 | $39.1M | $689.9M | ||
| Q2 25 | $44.3M | $652.8M | ||
| Q1 25 | $27.8M | $580.7M | ||
| Q4 24 | — | $517.6M | ||
| Q3 24 | — | $442.3M | ||
| Q2 24 | — | $375.7M | ||
| Q1 24 | — | $310.4M |
| Q4 25 | $150.6M | $954.3M | ||
| Q3 25 | $155.4M | $920.2M | ||
| Q2 25 | $148.7M | $856.0M | ||
| Q1 25 | $139.1M | $794.3M | ||
| Q4 24 | — | $727.6M | ||
| Q3 24 | — | $660.9M | ||
| Q2 24 | — | $608.7M | ||
| Q1 24 | — | $561.4M |
| Q4 25 | $326.5M | $1.1B | ||
| Q3 25 | $318.2M | $1.1B | ||
| Q2 25 | $308.3M | $971.9M | ||
| Q1 25 | $290.0M | $908.9M | ||
| Q4 24 | — | $851.4M | ||
| Q3 24 | — | $772.0M | ||
| Q2 24 | — | $706.4M | ||
| Q1 24 | — | $646.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | $44.9M |
| Free Cash FlowOCF − Capex | $1.7M | $44.9M |
| FCF MarginFCF / Revenue | 1.4% | 29.4% |
| Capex IntensityCapex / Revenue | 5.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.01× | 0.85× |
| TTM Free Cash FlowTrailing 4 quarters | $37.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $44.9M | ||
| Q3 25 | $4.2M | $32.4M | ||
| Q2 25 | $27.8M | $71.3M | ||
| Q1 25 | $19.5M | $60.0M | ||
| Q4 24 | — | $70.9M | ||
| Q3 24 | — | $72.9M | ||
| Q2 24 | — | $64.1M | ||
| Q1 24 | — | $31.9M |
| Q4 25 | $1.7M | $44.9M | ||
| Q3 25 | $793.0K | — | ||
| Q2 25 | $24.9M | $71.3M | ||
| Q1 25 | $9.8M | — | ||
| Q4 24 | — | $70.8M | ||
| Q3 24 | — | $72.6M | ||
| Q2 24 | — | $64.1M | ||
| Q1 24 | — | $31.7M |
| Q4 25 | 1.4% | 29.4% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 19.4% | 48.6% | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | — | 49.9% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | 32.2% |
| Q4 25 | 5.3% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 2.3% | 0.0% | ||
| Q1 25 | 6.5% | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | 1.01× | 0.85× | ||
| Q3 25 | 0.34× | 0.61× | ||
| Q2 25 | 1.81× | 1.37× | ||
| Q1 25 | 0.90× | 1.06× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 1.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBW
| Direct To Consumer | $112.3M | 92% |
| Commercial Product And Service | $8.9M | 7% |
| International Franchising | $1.5M | 1% |
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
